Qlosi Eye Drops is a cholinergic agonist used for the treatment of presbyopia in adults.
How to Use Qlosi Eye Drops
Routine Usage
Single Dose: Instill 1 drop of Qlosi into each eye. The maximum frequency of use is 2 times per day, with an interval of 2-3 hours between the two doses, and the effect can last for approximately 8 hours.
Usage Frequency: It can be used regularly every day or on an as-needed basis.
Usage Steps
Hand Hygiene: Clean your hands to avoid contaminating the vial or eyes.
Contact Lens Handling: Remove contact lenses before using the eye drops, and wait for 10 minutes after instillation before reinserting the contact lenses.
Administration Technique: Avoid contact between the tip of the vial and the eyes or any surfaces to prevent contamination or eye scratches.
Dosage Adjustment of Qlosi Eye Drops
Routine Dosage Adjustment
The basic dosage of Qlosi is 1 drop per dose, 1 to 2 times a day.
The total number of administrations per day should not exceed 2 times. Excessive use may increase the risk of adverse reactions.
Adjustment Based on Efficacy Response
In two key clinical trials, NEAR-1 and NEAR-2, approximately 39-52% of patients showed good efficacy 1-2 hours after administration.
If a patient does not achieve the desired effect after using the drug according to the standard regimen, they should consult an ophthalmologist instead of increasing the dosage or usage frequency on their own.
Use of Qlosi Eye Drops in Special Populations
Use in Pregnant Women
Currently, there is a lack of adequate and well-controlled studies on the use of Qlosi in pregnant women.
Animal studies have shown that when the oral dose is approximately 1,200 times the maximum recommended ophthalmic dose for humans, it may cause maternal toxicity, fetal skeletal abnormalities, and weight loss.
Pregnant women should use this drug with caution after weighing the pros and cons. It should only be used when clearly necessary, and the lowest effective dose should be used as much as possible.
Use in Lactating Women
There is no data indicating whether pilocarpine, the active ingredient in Qlosi, passes into human breast milk.
Animal experiments have shown that radiolabeled pilocarpine can be excreted through breast milk.
Considering that infants are highly sensitive to cholinergic drugs, lactating women should closely monitor the infant's condition when using this drug, or consider suspending breastfeeding.
Clinical decisions should comprehensively consider the benefits of breastfeeding and the potential risks of the drug to the infant.
